New heart failure drug shows promise in early safety trial
NCT ID NCT04045405
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This early-stage study tested a new drug called CDR132L in 28 people with stable heart failure caused by reduced blood flow to the heart. The main goal was to check if the drug is safe and how the body processes it. Researchers compared the drug against a placebo to see any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge
London, SE1 1YR, United Kingdom
Conditions
Explore the condition pages connected to this study.